10 Affordable Biotech Stocks to Buy Right Now
In this article, we will take a look at some of the most affordable biotech stocks that are currently offering attractive upside potential.
Palvella Therapeutics Inc. (PVLA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 1,135,406 | $173,512,745 | -2% | 3.17% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 672,789 | $102,815,615 | -30% | 2.63% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 317,517 | $48,522,948 | 0.15% | |
| 4. | OrbiMed Advisors Samuel Isaly | 292,360 | $44,678,455 | +118% | 0.83% |
| 5. | Siren L.L.C. Raymond Debbane | 257,485 | $39,348,858 | 0.8% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $112.30 | 445 | $49,973.50 | 187,616 | 2026-03-30 | Filing | |
| $125.00 | 4,000 | $500,000.00 | 187,171 | 2026-02-27 | Filing | |
| $125.00 | 2,400 | $300,000.00 | 47,812 | 2026-02-27 | Filing | |
| $20.27 | 2,490 | $50,472.30 | 13,516 | 2025-04-09 | Filing | |
| $20.13 | 2,500 | $50,325.00 | 183,171 | 2025-04-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $151.33 | 560 | $84,742.73 | 160,116 | 2026-09-15 | Filing | |
| $150.40 | 263 | $39,556.38 | 160,676 | 2026-09-15 | Filing | |
| $149.38 | 954 | $142,506.52 | 160,939 | 2026-09-15 | Filing | |
| $153.10 | 1,560 | $238,834.44 | 161,893 | 2026-09-14 | Filing | |
| $152.12 | 6,160 | $937,033.94 | 163,453 | 2026-09-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 960,619 | $146,801,795 | 0.09% | |
| 2. | 918,357 | $140,343,317 | 0% | |
| 3. | 882,400 | $134,848,368 | 2.94% | |
| 4. | 771,901 | $117,961,911 | 7.17% | |
| 5. | 653,172 | $99,817,745 | 0% |
News See All
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin
With strong 1-year returns and upside potential, Palvella Therapeutics, Inc. (NASDAQ:PVLA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.
12 Best Multibagger Stocks to Buy Heading into 2026
In this article, we discuss the 12 Best Multibagger Stocks to Buy Heading into 2026.
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin
Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the best-performing NASDAQ stocks according to analysts.
12 Best Performing NASDAQ Stocks According to Analysts
On July 3, Dan Ives, the Global Head of Tech Research at Wedbush, appeared on CNBC to suggest that AI will fuel a multi-year tech rally.
Why These 15 Healthcare Stocks Are Surging in 2025
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year.
11 Best Performing NASDAQ Stocks So Far in 2025
On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s 'Closing Bell Overtime' to discuss the current volatility in the tech sector, especially the NASDAQ.
11 Best Performing Stocks So Far In 2025
On March 21, Jason Pride, Chief of Investment Strategy at Glenmede, and Stephen DeNichilo, Portfolio Manager at Federated Hermes, appeared on CNBC's 'Power Lunch' to discuss the current market dynamics...
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
Hedge Fund Resource Center